Psychological well being app Lissun luggage $3M for AI integration
Psychological well being platform Lissun in India has scored $2.5 million in a pre-Collection A funding spherical led by RPSG Capital Ventures.
With its contemporary funds, the startup plans to combine AI into its suite of digital psychological well being options which goal corporates, colleges, and households of kids with neurodevelopmental situations. The brand new funds will even go to increasing their providers and rising their group.
Proceeds from this new investing spherical carry its complete funding to $5 million. Lissun final raised over $1 million in seed funding in September of the earlier 12 months.
Asan Medical Heart first to prescribe locally-approved imaginative and prescient loss DTx
Asan Medical Heart (AMC), considered one of South Korea’s greatest hospitals, has began prescribing a Korean-made digital therapeutic for visible impairment because of stroke.
The mobile-based utility Vivid Mind supplies coaching by way of digital actuality to boost a person’s response to visible stimuli.
AMC formally prescribed the answer in September, 5 months after it was cleared by the Korean authorities – the third for a neighborhood DTx.
AMC professor Kang Dong-hwa, who developed Vivid Mind with Nunaps (a neighborhood firm he based), now plans to broaden their DTx to hospitals regionally and overseas.
Neurophet’s newest collab to foretell Alzheimer’s threat
Korean medical imaging AI firm Neurophet has introduced a brand new partnership that may develop a brand new Alzheimer’s illness analysis platform.
In an announcement, the corporate mentioned it is going to collaborate with native biotechnology agency Aribio, which develops remedy for neurodegenerative illnesses.
They intend to combine Neurophet’s MRI-based picture evaluation software program with Aribio’s blood-based Alzheimer’s diagnostic check to detect early individuals with Alzheimer’s-positive amyloid beta protein deposits of their brains.
Their answer, in line with a press launch, seeks to make Alzheimer’s testing extra accessible, decreasing repeat testing with the expensive amyloid-PET imaging.
Neurophet and Aribio’s collaboration builds on their present work within the world scientific trial of Aribio’s oral Alzheimer’s remedy AR1001, part 3.
In July, Neurophet unveiled the Neurophet AQUA AD, its newest Alzheimer’s remedy prescription and monitoring software program.
